Kamal Sharma

Union Minister Vijay Sampla on Monday said that while his department would provide Rs 200 crore to the Industrial Finance Corporation of India (IFCI), the latter would add Rs 50 crore to it from its own resources for the Fund.

Yen depreciation to impact Japan business revenue: Lupin

A third of Lupin‘s 72 products are market leaders. The company remains positive on its business outlook.

See Q2 better than Q1; US biz growth in 25-30% range: Lupin

According to Kamal Sharma, Lupin should perform better in Q2 than Q1 and eyes double digit growth as against virtually no growth in Q1.

Lupin aims to be specialist co; eyes more branded products

Lupin wants to step in the next phase of growth by transforming itself in to a speciality company, plans to pump more of its branded products going forward.

Attention to margins, quality doubles Lupin Q4 net: MD

Kamal Sharma, MD, Lupin Ltd says, in an interview to CNBC-TV18, that the attention to margins, quality and control on costs caused fourth-quarter net to double

See 23% margins by FY13 end; Indian biz at 18%: Lupin

In an interview to CNBC-TV18, Kamal Sharma, managing director, Lupin gives his reaction on the company's positive Q3 results. The company's results beat expectations with itts profits jumping 43% to Rs 335 crore.

Lupin to focus on new product infusion in FY13

Higher tax expenses led to a decline in consolidated net profit of pharma company, Lupin in the fourth quarter of FY12. The company posted a decline of 31% year-on-year to Rs 156 crore. However, net sales were up 25% between January-March at Rs 1,883.2 crore.

Lupin Q3 cons net up 5% YoY at Rs 235 cr

Pharma company Lupin's consolidated net profit for the third quarter rose 5% year-on-year at Rs 235.1 crore as strong sales growth was offset by higher tax expenses.

Lupin says working on 10 promising lead molecules

Lupin has always been very shy in discussing their drug discovery pipeline. However, in an exclusive interview with CNBC-TV18, Dr Kamal Sharma, said that the company is excited about the R&D pipeline, which has 10 lead molecules, and could be potential out-licencing targets by next year.

Margin pressure temporary; sales to grow 20-25%: Lupin

Kamal Sharma, managing director, Lupin in an interview with CNBC-TV18 said, growth in this quarter was driven by markets in India, Japan and South Africa.

Exporter's Diary takes a look at pharma industry

On the show: A look at USD 20 billion pharmaceutical industry of which exports constitute over 50%. To give an insight into the pharma sector Dr. Kamal Sharma, Managing Director of Lupin joins with more details.

Lupin actively eyeing buys in Latin America

Lupin is actively evaluating acquisition opportunities in Latin America, its managing director said on Thursday.

What is Lupin's acquisition agenda for the future?

Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.